Hospital
ST Mary's Hospital Medical Center of Green Bay Inc.-Hospital Sisters
ST Mary's Hospital Medical Center of Green Bay Inc.-Hospital Sisters was paid $12.79M by Medicaid between Jan 2018 and Dec 2024, across 209 billing codes. Its largest line is 99283, emergency room visit (moderate) — 18% of everything it billed.
33Billing provider infoST MARY'S HOSPITAL MEDICAL CENTER OF GREEN BAY INC.-HOSPITAL SISTERS
GREEN BAY, WI 54303
GREEN BAY, WI 54303
33aNPI1649246877assigned 02/27/2006
33bProvider typeGeneral Acute Care Hospital
28Total paid$12.79M
24GClaims529,330
24DCodes billed209
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in Wisconsin
Rank by total paid#14 of 60
Median peer was paid$2.90M
This provider vs. median4.4×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 77,066 | $2.17M | |
| 2019 | 78,587 | $2.14M | |
| 2020 | 71,329 | $1.65M | |
| 2021 | 80,746 | $1.73M | |
| 2022 | 83,617 | $1.83M | |
| 2023 | 78,903 | $1.87M | |
| 2024incomplete | 59,082 | $1.40M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 18% | 32,204 | 28,487 | $2.30M |
| 96361 | Intravenous infusion, hydration; each additional hour | 11% | 9,520 | 7,774 | $1.35M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 7.9% | 19,085 | 16,688 | $1.01M |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 7.7% | 11,800 | 10,715 | $990K |
| 41899 | Unlisted procedure, dentoalveolar structures | 6.5% | 2,109 | 1,809 | $832K |
| 80053 | Comprehensive metabolic panel | 4.9% | 26,377 | 22,064 | $622K |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 3.5% | 8,932 | 7,797 | $454K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 2.5% | 4,752 | 2,865 | $320K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | 2.2% | 2,839 | 2,501 | $283K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 2.1% | 4,035 | 3,651 | $270K |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | 2.0% | 1,472 | 1,371 | $254K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | 1.8% | 4,567 | 3,970 | $235K |
197 more codes
| 70450 | Computed tomography, head or brain; without contrast material | 1.8% | 3,398 | $224K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 1.5% | 29,888 | $190K |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | 1.3% | 5,646 | $172K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | 1.2% | 3,081 | $152K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | 1.2% | 3,705 | $149K |
| 80048 | Basic metabolic panel (calcium, ionized) | 1.0% | 7,247 | $130K |
| 81025 | <1% | 8,897 | $122K | |
| 87430 | <1% | 3,518 | $117K | |
| 87081 | <1% | 2,353 | $114K | |
| G0123 | Screening cytopathology, cervical or vaginal (any reporting system), collected in preservative fluid, automated thin layer preparation, screening by cytotechnologist under physician supervision | <1% | 5,951 | $111K |
| 87624 | Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types | <1% | 3,590 | $108K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 1,212 | $107K |
| G0378 | Hospital observation service, per hour | <1% | 2,592 | $107K |
| 81001 | <1% | 17,902 | $105K | |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 1,458 | $105K |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | <1% | 2,887 | $101K |
| 84484 | <1% | 9,457 | $100K | |
| 80306 | <1% | 2,802 | $97K | |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 1,391 | $97K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 2,464 | $96K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 2,458 | $85K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 4,548 | $72K |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 6,915 | $66K |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 1,544 | $64K |
| 45385 | Colonoscopy, flexible; with removal of tumor(s), polyp(s), or other lesion(s) | <1% | 300 | $61K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 3,997 | $53K |
| 83690 | <1% | 8,519 | $49K | |
| 84702 | <1% | 1,964 | $49K | |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 529 | $45K |
| 87210 | <1% | 2,222 | $41K | |
| 12001 | <1% | 405 | $38K | |
| 80061 | Lipid panel | <1% | 2,984 | $36K |
| 87077 | <1% | 1,983 | $36K | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 3,821 | $32K |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | <1% | 443 | $31K |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | <1% | 112 | $30K |
| 80050 | General health panel | <1% | 1,994 | $30K |
| 83880 | <1% | 1,370 | $28K | |
| 85379 | <1% | 2,818 | $24K | |
| 83735 | <1% | 4,400 | $23K | |
| 83605 | <1% | 2,813 | $22K | |
| 84439 | <1% | 2,257 | $21K | |
| 85610 | <1% | 3,793 | $20K | |
| 45380 | Colonoscopy, flexible; with biopsy, single or multiple | <1% | 124 | $20K |
| 87807 | <1% | 864 | $20K | |
| 87040 | <1% | 2,778 | $19K | |
| 78452 | Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress | <1% | 123 | $17K |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 748 | $17K |
| 29125 | <1% | 160 | $16K | |
| 82565 | <1% | 852 | $14K | |
| 85027 | <1% | 1,748 | $14K | |
| 86140 | <1% | 2,858 | $13K | |
| 73721 | Magnetic resonance imaging, any joint of lower extremity; without contrast material | <1% | 149 | $13K |
| 87186 | <1% | 1,797 | $12K | |
| 70496 | <1% | 174 | $11K | |
| 70498 | <1% | 164 | $11K | |
| 93017 | <1% | 240 | $11K | |
| 99213 | Doctor's office visit, returning patient (routine) | <1% | 444 | $10K |
| 70553 | Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences | <1% | 112 | $10K |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 170 | $9K |
| 87088 | <1% | 1,440 | $9K | |
| 82728 | <1% | 749 | $9K | |
| 71046 | Radiologic examination, chest; 2 views | <1% | 2,406 | $8K |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 224 | $8K |
| 86480 | <1% | 113 | $8K | |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 14,730 | $7K |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 171 | $7K |
| 85730 | <1% | 1,897 | $7K | |
| 82950 | <1% | 879 | $7K | |
| 86481 | <1% | 81 | $7K | |
| 93971 | <1% | 203 | $5K | |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 72 | $5K |
| 12011 | <1% | 40 | $5K | |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 198 | $4K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 14,973 | $4K |
| 85652 | <1% | 1,773 | $4K | |
| 94664 | <1% | 204 | $4K | |
| 87486 | <1% | 112 | $4K | |
| 71045 | Radiologic examination, chest; single view | <1% | 8,403 | $3K |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 10,068 | $3K |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 202 | $3K |
| 87070 | <1% | 125 | $3K | |
| 90715 | <1% | 456 | $3K | |
| 83550 | <1% | 446 | $3K | |
| 85018 | <1% | 743 | $3K | |
| 87581 | <1% | 112 | $3K | |
| 76830 | Ultrasound, transvaginal | <1% | 58 | $3K |
| 80076 | <1% | 340 | $2K | |
| 83540 | <1% | 465 | $2K | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 6,446 | $2K |
| 82805 | <1% | 95 | $2K | |
| 74018 | <1% | 384 | $2K | |
| 84145 | <1% | 95 | $1K | |
| 76536 | <1% | 27 | $1K | |
| 70551 | Magnetic resonance imaging, brain; without contrast material | <1% | 14 | $1K |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 138 | $1K |
| 0042T | <1% | 28 | $1K | |
| G0379 | Direct admission of patient for hospital observation care | <1% | 31 | $969.29 |
| 74178 | <1% | 12 | $914.11 | |
| 88304 | <1% | 109 | $913.71 | |
| 86900 | <1% | 407 | $889.28 | |
| 86901 | <1% | 407 | $889.02 | |
| 73630 | <1% | 932 | $751.09 | |
| 70486 | <1% | 29 | $746.59 | |
| 12002 | <1% | 14 | $733.47 | |
| 93225 | <1% | 43 | $704.10 | |
| 86850 | <1% | 103 | $653.37 | |
| 88312 | <1% | 938 | $643.47 | |
| 88174 | <1% | 47 | $635.77 | |
| 93010 | Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only | <1% | 89 | $541.55 |
| 99214 | Doctor's office visit, returning patient (more involved) | <1% | 13 | $484.82 |
| 72100 | <1% | 201 | $439.71 | |
| 73562 | <1% | 506 | $380.27 | |
| 97535 | Self-care/home management training, each 15 minutes | <1% | 56 | $368.17 |
| 88112 | <1% | 15 | $359.41 | |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 17,412 | $323.24 |
| 73502 | <1% | 62 | $317.59 | |
| 85007 | <1% | 63 | $272.29 | |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | <1% | 14 | $260.91 |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 8,187 | $226.24 |
| 36415 | Collection of venous blood by venipuncture | <1% | 2,671 | $214.20 |
| 82550 | <1% | 51 | $212.57 | |
| 73610 | <1% | 1,008 | $196.99 | |
| 82607 | <1% | 14 | $180.25 | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 11,012 | $172.82 |
| J0689 | Injection, cefazolin sodium (baxter), not therapeutically equivalent to j0690, 500 mg | <1% | 532 | $158.07 |
| 97162 | <1% | 16 | $147.22 | |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 2,974 | $141.67 |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 1,429 | $137.20 |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 9,553 | $119.72 |
| 82150 | <1% | 14 | $115.57 | |
| 73130 | <1% | 460 | $103.14 | |
| 93226 | <1% | 29 | $103.05 | |
| 84703 | <1% | 16 | $93.71 | |
| 96376 | <1% | 2,393 | $83.86 | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 425 | $81.34 |
| J3490 | Unclassified drugs | <1% | 7,026 | $80.05 |
| 73030 | <1% | 391 | $66.29 | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 6,240 | $56.80 |
| 88342 | <1% | 13 | $47.83 | |
| P9612 | Catheterization for collection of specimen, single patient, all places of service | <1% | 360 | $42.33 |
| A9577 | Injection, gadobenate dimeglumine (multihance), per ml | <1% | 1,811 | $37.89 |
| 73110 | <1% | 283 | $34.07 | |
| 99152 | <1% | 190 | $22.88 | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 3,265 | $19.07 |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | <1% | 1,123 | $14.81 |
| 88313 | <1% | 96 | $7.12 | |
| J3480 | Injection, potassium chloride, per 2 meq | <1% | 66 | $6.81 |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 11,585 | $5.70 |
| 73560 | <1% | 54 | $4.22 | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 7,288 | $1.74 |
| J3475 | Injection, magnesium sulfate, per 500 mg | <1% | 108 | $1.39 |
| J2704 | Injection, propofol, 10 mg | <1% | 10,394 | $1.15 |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 3,382 | $1.04 |
| C1713 | Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable) | <1% | 704 | $0.96 |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 2,167 | $0.90 |
| J2795 | Injection, ropivacaine hydrochloride, 1 mg | <1% | 824 | $0.50 |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 3,899 | $0.49 |
| J0171 | Injection, adrenalin, epinephrine, 0.1 mg | <1% | 704 | $0.25 |
| Q9969 | Tc-99m from non-highly enriched uranium source, full cost recovery add-on, per study dose | 0% | 454 | $0.00 |
| A9270 | Non-covered item or service | 0% | 2,692 | $0.00 |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | 0% | 175 | $0.00 |
| A9500 | Technetium tc-99m sestamibi, diagnostic, per study dose | 0% | 196 | $0.00 |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | 0% | 847 | $0.00 |
| J2371 | Injection, phenylephrine hydrochloride, 20 micrograms | 0% | 188 | $0.00 |
| J2175 | Injection, meperidine hydrochloride, per 100 mg | 0% | 384 | $0.00 |
| J2060 | Injection, lorazepam, 2 mg | 0% | 1,432 | $0.00 |
| J2370 | Injection, phenylephrine hcl, up to 1 ml | 0% | 306 | $0.00 |
| J0131 | Injection, acetaminophen, not otherwise specified,10 mg | 0% | 166 | $0.00 |
| C1769 | Guide wire | 0% | 103 | $0.00 |
| J1790 | Injection, droperidol, up to 5 mg | 0% | 488 | $0.00 |
| 99153 | Mod sedat endo service >5yrs | 0% | 39 | $0.00 |
| J7050 | Infusion, normal saline solution, 250 cc | 0% | 52 | $0.00 |
| J8540 | Dexamethasone, oral, 0.25 mg | 0% | 34 | $0.00 |
| J2003 | Injection, lidocaine hydrochloride, 1 mg | 0% | 92 | $0.00 |
| J1630 | Injection, haloperidol, up to 5 mg | 0% | 24 | $0.00 |
| 74019 | 0% | 49 | $0.00 | |
| J2785 | Injection, regadenoson, 0.1 mg | 0% | 15 | $0.00 |
| 71101 | 0% | 15 | $0.00 | |
| 72040 | 0% | 12 | $0.00 | |
| J2270 | Injection, morphine sulfate, up to 10 mg | 0% | 2,202 | $0.00 |
| G1004 | Clinical decision support mechanism national decision support company, as defined by the medicare appropriate use criteria program | 0% | 1,310 | $0.00 |
| J3370 | Injection, vancomycin hcl, 500 mg | 0% | 223 | $0.00 |
| 73140 | 0% | 27 | $0.00 | |
| J2550 | Injection, promethazine hcl, up to 50 mg | 0% | 192 | $0.00 |
| J2272 | Injection, morphine sulfate (fresenius kabi), not therapeutically equivalent to j2270, up to 10 mg | 0% | 77 | $0.00 |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | 0% | 308 | $0.00 |
| J1644 | Injection, heparin sodium, per 1000 units | 0% | 464 | $0.00 |
| J0665 | Injection, bupivicaine, not otherwise specified, 0.5 mg | 0% | 224 | $0.00 |
| C9113 | Injection, pantoprazole sodium, per vial | 0% | 39 | $0.00 |
| J2710 | Injection, neostigmine methylsulfate, up to 0.5 mg | 0% | 125 | $0.00 |
| J0780 | Injection, prochlorperazine, up to 10 mg | 0% | 13 | $0.00 |
| 73080 | 0% | 17 | $0.00 | |
| J1171 | Injection, hydromorphone, 0.1 mg | 0% | 19 | $0.00 |
| J1650 | Injection, enoxaparin sodium, 10 mg | 0% | 303 | $0.00 |
| 73590 | 0% | 15 | $0.00 | |
| C1776 | Joint device (implantable) | 0% | 14 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialCHARLIER, BRIAN (COO)
| Provider | Location | Paid |
|---|---|---|
| ST. Vincent Hospital-Hospital Sisters-Third Order of ST. Francis | Green Bay, WI | $627K |
| ST Mary's Hospital Medical Center of Green Bay Inc.-Hospital Sisters | Green Bay, WI | $106K |
| ST Vincent Hospital-Hospital Sisters-Third Order of ST Francis | Marinette, WI | $59K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.